Literature DB >> 33658780

Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis.

Chenzhe Gao1,2, Shen Yu2, Xiaonan Zhang3, Yanxin Dang2,4, Dan-Dan Han2, Xin Liu2,5, Janchun Han1, Mizhou Hui1.   

Abstract

AIM: Iridoid glycosides (IG) as the major active fraction of Syringa oblata Lindl. has a proven anti-inflammatory effect for ulcerative colitis (UC). However, its current commercial formulations are hampered by low bioavailability and unable to reach inflamed colon. To overcome the limitation, dual functional IG-loaded nanoparticles (DFNPs) were prepared to increase the residence time of IG in colon. The protective mechanism of DFNPs on DSS-induced colonic injury was evaluated in rats.
MATERIALS AND METHODS: We prepared DFNPs using the oil-in-water emulsion method. PLGA was selected as sustained-release polymer, and ES100 and EL30D-55 as pH-responsive polymers. The morphology and size distribution of NPs were measured by SEM and DLS technique. To evaluate colon targeting of DFNPs, DiR, was encapsulated as a fluorescent probe into NPs. Fluorescent distribution of NPs were investigated. The therapeutic potential and in vivo transportation of NPs in gastrointestinal tract were evaluated in a colitis model.
RESULTS: SEM images and zeta data indicated the successful preparation of DFNPs. This formulation exhibited high loading capacity. Drug release results suggested DFNPs released less than 20% at the first 6 h in simulated gastric fluid (pH1.2) and simulated small intestine fluid (pH6.8). A high amount of 84.7% sustained release from NPs in simulated colonic fluid (pH7.4) was beyond 24 h. DiR-loaded NPs demonstrated a much higher colon accumulation, suggesting effective targeting due to functionalization with pH and time-dependent polymers. DFNPs could significantly ameliorate the colonic damage by reducing DAI, macroscopic score, histological damage and cell apoptosis. Our results also proved that the potent anti-inflammatory effect of DFNPs is contributed by decrease of NADPH, gene expression of COX-2 and MMP-9 and the production of TNF-α, IL-17, IL-23 and PGE2.
CONCLUSION: We confirm that DFNPs exert protective effects through inhibiting the inflammatory response, which could be developed as a potential colon-targeted system.
© 2021 Gao et al.

Entities:  

Keywords:  Syringa oblata Lindl.; colon-targeted nanoparticles; iridoid glycoside; pH-sensitive and time-dependent; ulcerative colitis

Mesh:

Substances:

Year:  2021        PMID: 33658780      PMCID: PMC7917316          DOI: 10.2147/IJN.S291090

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  32 in total

1.  IBD: selective nanoparticle adhesion can enhance colitis therapy.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 46.802

Review 2.  Roles of Cyclooxygenase, Prostaglandin E2 and EP Receptors in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract.

Authors:  Koji Takeuchi; Kikuko Amagase
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

3.  Correction to: NADPH Oxidases in Inflammatory Bowel Disease.

Authors:  Emily Stenke; Billy Bourke; Ulla G Knaus
Journal:  Methods Mol Biol       Date:  2019

Review 4.  Drug delivery strategies in the therapy of inflammatory bowel disease.

Authors:  Christian Lautenschläger; Carsten Schmidt; Dagmar Fischer; Andreas Stallmach
Journal:  Adv Drug Deliv Rev       Date:  2013-10-22       Impact factor: 15.470

5.  WGCNA Reveals Key Roles of IL8 and MMP-9 in Progression of Involvement Area in Colon of Patients with Ulcerative Colitis.

Authors:  Xue Lin; Jin Li; Qiu Zhao; Jue-Rong Feng; Qian Gao; Jia-Yan Nie
Journal:  Curr Med Sci       Date:  2018-04-30

6.  Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol.

Authors:  Qingxia Guan; Shuang Sun; Xiuyan Li; Shaowa Lv; Ting Xu; Jialin Sun; Wenjing Feng; Liang Zhang; Yongji Li
Journal:  J Mater Sci Mater Med       Date:  2015-12-24       Impact factor: 3.896

7.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.

Authors:  Daniel N Frank; Allison L St Amand; Robert A Feldman; Edgar C Boedeker; Noam Harpaz; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-15       Impact factor: 11.205

8.  Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers.

Authors:  Enas El-Maghawry; Mina I Tadros; Seham A Elkheshen; Ahmed Abd-Elbary
Journal:  Int J Nanomedicine       Date:  2020-06-08

9.  Preparation and evaluation of duloxetine hydrochloride enteric-coated pellets with different enteric polymers.

Authors:  Chen Kuang; Yinghua Sun; Bing Li; Rui Fan; Jing Zhang; Yumin Yao; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2016-08-31       Impact factor: 6.598

Review 10.  Advanced nanomedicines for the treatment of inflammatory diseases.

Authors:  Romain Brusini; Mariana Varna; Patrick Couvreur
Journal:  Adv Drug Deliv Rev       Date:  2020-07-19       Impact factor: 15.470

View more
  3 in total

1.  All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis.

Authors:  Xiangji Yan; Chunhua Yang; Mei Yang; Yana Ma; Yuanyuan Zhang; Yujie Zhang; Cui Liu; Qiuran Xu; Kangsheng Tu; Mingzhen Zhang
Journal:  J Nanobiotechnology       Date:  2022-03-02       Impact factor: 10.435

2.  The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis.

Authors:  Amira Motawea; Walaa Ebrahim Abd El Hady; Ghada Ahmed El-Emam
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

Review 3.  Neuroprotective effects of Morinda officinalis How.: Anti-inflammatory and antioxidant roles in Alzheimer's disease.

Authors:  Yi Zhang; Meng Zhang
Journal:  Front Aging Neurosci       Date:  2022-09-08       Impact factor: 5.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.